FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022296886> ?p ?o ?g. }

• W2022296886 abstract "complex diseases is limited by a still rudimentary understanding of the molecular basis of disease as well as of drug action. At the heart of this is our current inability to account for inter-individual differences in disease etiology and drug response. These inter-individual differences are determined, to a large extent, by inherited predispositions and susceptibilities. Knowledge of the genetic differences that explain these individual characteristics, and based upon it, the development of specific diagnostics and therapeutics, will therefore be critical for the successful transition to a future progress in health care.The impact of genetics and genomics will leave its mark along all steps involved in the creation of a new medicine: in the discovery of new targets that carry-inherently, because genetic linkage implies causation-a greater likelihood of success; in the discovery phase of a new drug aimed at an existing target, where the knowledge of molecular variation of this target (SNPs) may provide clues to achieve higher selectivity; where genetic epidemiology studies will provide added value by validating the target; and where large scale gene expression profiling (gene chips) will help select compounds with a higher likelihood for ultimate success at an early stage; and in the development phase of an drug undergoing clinical evaluation, where pharmacogenetic studies, and genotype-specific patient selection may allow recognition and definition of drug-responders and non-responders, or help decrease the likelihood of adverse events. Although the impact of genetic and genomic investigation will certainly accelerate progress in biomedical research, we believe it will do so in an evolutionary fashion, and as a logical extension of the history of medical progress towards a more detailed understanding of disease and the resultant more refined differential diagnosis as well as more accurate prospective risk assessment. If any, the fundamental change we are going to witness in the years to come is a (paradigmatic) shift from today's largely clinical disease definition and diagnosis to a molecular definition and diagnosis of disease. This shift is likely to greatly increase the importance of in-vitro diagnostics and will mandate, much more than is the case today, an integrated approach of diagnostics and therapeutics. Ultimately, we expert to derive the benefit of more successful, and more cost-effective medicines, and of possibly being able to prevent (or delay), rather than treat disease.It is important to realize that genetic research and testing are areas of great public concern, and that a more comprehensive dialogue between scientists and the public is urgently needed to address the societal, ethical, legal issues that are being raised. Only then will we be able to truly take advantage of the significant advances in medical knowledge that genetic research will make possible, and fully realize the potential of these approaches towards the ultimate goal of all our striving, improving the human condition.The utility of most drugs prescribed today for common, complex diseases is limited by a still rudimentary understanding of the molecular basis of disease as well as of drug action. At the heart of his is our current inability to account for inter-individual differences in disease etiology and drug response. These inter-individual differences are determined, to a large extent, by inherited predispositions and susceptibilities. Knowledge of the genetic differences that explain these individual characteristics, and based upon it, the development of specific diagnostics and therapeutics, will therefore be critical for the successful transition to a future progress in health care.The impact of genetics and genomics will leave its mark along all steps involved in the creation of a new medicine: in the discovery of new targets that carry-inherently, because genetic linkage implies causation-a greater likelihood of success; in the discovery of a new drug aimed at an existing target, where the knowledge of molecular variation of this target (SNPs) may provide clues to achieve higher selectivity; where genetic apidemiology studies will provide added value by validating the target; and where large scale gene expression profiling (gene chips) will help select compounds with a higher likelihood for ultimate success at an early stage; and in the development phase of an drug undergoing clinical evaluation, where pharmacogenetic studies, and genotype-specific patient selection may allow recognition and definition of drug-responders and non-responders, or help decrease the likelihood of adverse events. Although the impact of genetic and genomic investigation will certainly accelerate progress in biomedical research, we believe it will do so in an evolutionary fashion, and as a logical extension of the history of medical progress towards a more detailed understanding of disease and the resultant more refined differential diagnosis as well as more accurate prospective risk assessment. If any, the fundamental change we are going to witness in the years to come is a (paradigmatic) shift from today's largely clinical disease definition and diagnosis to a molecular definition and diagnosis of disease. This shift is likely to greatly increase the importance of in-vitro diagnostics and will mandate, much more than is the case today, an integrated approach of diagnostics and therapeutics. Ultimately, we expect to derive the benefit of more successful, and more cost-effective medicines, and of possibly being able to prevent (or delay), rather than treat disease.It is important to realize that genetic research and testing are areas of great public concern, and that a more comprehensive dialogue between scientists and the public is urgently needed to address the societal, ethical, legal issues that are being raised. Only then will we be able to truly take advantage of the significant advances in medical knowledge that genetic research will make possible, and fully realize the potential of these approaches towards the ultimate goal of all our striving, improving the human condition." @default.
• W2022296886 created "2016-06-24" @default.
• W2022296886 creator A5060041987 @default.
• W2022296886 date "2001-04-22" @default.
• W2022296886 modified "2023-09-24" @default.
• W2022296886 title "Genetics and genemoics" @default.
• W2022296886 doi "https://doi.org/10.1145/369133.369216" @default.
• W2022296886 hasPublicationYear "2001" @default.
• W2022296886 type Work @default.
• W2022296886 sameAs 2022296886 @default.
• W2022296886 citedByCount "0" @default.
• W2022296886 crossrefType "proceedings-article" @default.
• W2022296886 hasAuthorship W2022296886A5060041987 @default.
• W2022296886 hasConcept C41008148 @default.
• W2022296886 hasConcept C54355233 @default.
• W2022296886 hasConcept C78458016 @default.
• W2022296886 hasConcept C86803240 @default.
• W2022296886 hasConceptScore W2022296886C41008148 @default.
• W2022296886 hasConceptScore W2022296886C54355233 @default.
• W2022296886 hasConceptScore W2022296886C78458016 @default.
• W2022296886 hasConceptScore W2022296886C86803240 @default.
• W2022296886 hasLocation W20222968861 @default.
• W2022296886 hasOpenAccess W2022296886 @default.
• W2022296886 hasPrimaryLocation W20222968861 @default.
• W2022296886 hasRelatedWork W1991523530 @default.
• W2022296886 hasRelatedWork W2002128513 @default.
• W2022296886 hasRelatedWork W2020824267 @default.
• W2022296886 hasRelatedWork W2020838698 @default.
• W2022296886 hasRelatedWork W2031436818 @default.
• W2022296886 hasRelatedWork W2057739827 @default.
• W2022296886 hasRelatedWork W2075354549 @default.
• W2022296886 hasRelatedWork W2112463916 @default.
• W2022296886 hasRelatedWork W2119103177 @default.
• W2022296886 hasRelatedWork W2092874662 @default.
• W2022296886 isParatext "false" @default.
• W2022296886 isRetracted "false" @default.
• W2022296886 magId "2022296886" @default.
• W2022296886 workType "article" @default.